耐药淋球菌的备选治疗方案

doi:10.35541/cjd.20210828

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (3): 272-275.doi: 10.35541/cjd.20210828

耐药淋球菌的备选治疗方案

张瑾陈绍椿尹跃平

中国医学科学院北京协和医学院皮肤病医院参比实验室中国疾病预防控制中心性病控制中心，南京 210042

收稿日期:2021-11-14 修回日期:2022-05-28 发布日期:2024-03-04
通讯作者: 陈绍椿 E-mail:chensc@ncstdlc.org
基金资助:
“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项（2018ZX10101001-004-003）；江苏省高层次卫生人才“六个一工程”拔尖人才项目（LGY2019091）；西藏自治区自然科学基金［XZ2021R-ZY47（Z）］

Promising treatment options for antibiotic-resistant Neisseria gonorrhoeae

Zhang Jin, Chen Shaochun, Yin Yueping

Reference Laboratory of STD, Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for STD Control, Chinese Center for Disease Control and Prevention, Nanjing 210042, China

Received:2021-11-14 Revised:2022-05-28 Published:2024-03-04
Contact: Chen Shaochun E-mail:chensc@ncstdlc.org
Supported by:
National Science and Technology Major Project（2018ZX10101001-004-003）; Jiangsu Provincial High-level Health Personnel “Six One Project” Top Talent Project（LGY2019091）; Natural Science Foundation of Xizang Autonomous Region of China （XZ2021R-ZY47［Z］）

摘要/Abstract

摘要： 【摘要】头孢曲松是治疗淋病主要的一线用药，但淋球菌对多种抗生素广泛耐药。为减缓淋球菌的耐药，亟需寻找有效的备选治疗方案。本文从联合疗法、老药新用和新药研发3个方面综述可能有效的抗淋球菌药物。

关键词: 淋病, 淋病奈瑟球菌, 抗药性, 细菌, 备选治疗方案, 治疗策略

Abstract: 【Abstract】 At present, ceftriaxone remains the primary first-line agent for the treatment of gonorrhea. With widespread resistance of Neisseria gonorrhoeae to multiple antibiotics, it is urgent to seek effective alternative treatments to slow down the process of gonococcal antibiotic resistance. This review summarizes potentially effective anti-gonococcal agents in terms of combination therapy, recycling of old antibiotics and development of new drugs.

Key words: Gonorrhea, Neisseria gonorrhoeae, Antibiotic resistant, bacterial, Alternative treatments, Treatment strategy

张瑾陈绍椿尹跃平. 耐药淋球菌的备选治疗方案[J]. 中华皮肤科杂志, 2024,57(3):272-275. doi:10.35541/cjd.20210828

Zhang Jin, Chen Shaochun, Yin Yueping. Promising treatment options for antibiotic-resistant Neisseria gonorrhoeae[J]. Chinese Journal of Dermatology, 2024, 57(3): 272-275.doi:10.35541/cjd.20210828

参考文献 31

［1］	Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016［J］. Bull World Health Organ, 2019,97（8）:548⁃562P. doi: 10.2471/BLT.18.228486.
［2］	疾病预防控制局. 2019年全国法定传染病疫情概况［EB/OL］.（2021⁃03⁃12）［2021⁃11⁃10］.http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml.
［3］	Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future［J］. Clin Microbiol Rev, 2014,27（3）:587⁃613. doi: 10.1128/CMR. 00010⁃14.
［4］	Chen SC, Yuan LF, Zhu XY, et al. Sustained transmission of the ceftriaxone⁃resistant Neisseria gonorrhoeae FC428 clone in China［J］. J Antimicrob Chemother, 2020,75（9）:2499⁃2502. doi: 10.1093/jac/dkaa196.
［5］	Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021［J］. MMWR Recomm Rep, 2021,70（4）:1⁃187. doi: 10.15585/mmwr.rr7004a1.
［6］	Kenyon C, Laumen J, Van Dijck C, et al. Gonorrhoea treatment combined with population⁃level general cephalosporin and quinolone consumption may select for Neisseria gonorrhoeae antimicrobial resistance at the levels of NG⁃MAST genogroup: an ecological study in Europe［J］. J Glob Antimicrob Resist, 2020,23:377⁃384. doi: 10.1016/j.jgar.2020.10.022.
［7］	Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea［J］. Clin Infect Dis, 2014,59（8）:1083⁃1091. doi: 10.1093/cid/ciu521.
［8］	Hamasuna R, Ohnishi M, Matsumoto M, et al. In vitro activity of sitafloxacin and additional newer generation fluoroquinolones against ciprofloxacin⁃resistant Neisseria gonorrhoeae isolates［J］. Microb Drug Resist, 2018,24（1）:30⁃34. doi: 10.1089/mdr.2017. 0054.
［9］	Soge OO, Salipante SJ, No D, et al. In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance［J］. Antimicrob Agents Chemother, 2016,60（5）:3106⁃3111. doi: 10.1128/AAC. 02798⁃15.
［10］	Hook EW 3rd, Golden MR, Taylor SN, et al. Efficacy and safety of single⁃dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open⁃label, noninferiority, phase 3, multicenter, randomized study［J］. Sex Transm Dis, 2019,46（5）:279⁃286. doi: 10.1097/OLQ. 0000000000000971.
［11］	Barbee LA, Golden MR. Aztreonam for Neisseria gonorrhoeae: a systematic review and meta⁃analysis［J］. J Antimicrob Chemother, 2020,75（7）:1685⁃1688. doi: 10.1093/jac/dkaa108.
［12］	Barbee LA, Soge OO, Ocbamichael N, et al. Single⁃arm open⁃label clinical trial of two grams of aztreonam for the treatment of Neisseria gonorrhoeae［J］. Antimicrob Agents Chemother, 2020,65（1）. doi: 10.1128/AAC.01739⁃20.
［13］	Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?［J］. Antimicrob Agents Chemother, 2012,56（7）:3603⁃3609. doi: 10.1128/AAC.00326⁃12.
［14］	Eyre DW, Town K, Street T, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018［J］. Euro Surveill, 2019,24（10）. doi: 10.2807/1560⁃7917.ES.2019.24.10.1900147.
［15］	Lagacé⁃Wiens P, Adam HJ, Laing NM, et al. Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential［J］. J Antimicrob Chemother, 2017,72（8）:2273⁃2277. doi: 10.1093/jac/dkx147.
［16］	Quaye N, Cole MJ, Ison CA. Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime［J］. J Antimicrob Chemother, 2014,69（6）:1568⁃1571. doi: 10.1093/jac/dkt537.
［17］	Yang F, Yan J, Zhang J, et al. Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China［J］. Int J Antimicrob Agents, 2020,55（2）:105846. doi: 10.1016/j.ijantimicag.2019.11.003.
［18］	Hauser C, Hirzberger L, Unemo M, et al. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates［J］. Antimicrob Agents Chemother, 2015,59（3）:1605⁃1611. doi: 10. 1128/AAC.04536⁃14.
［19］	Tesh LD, Shaeer KM, Cho JC, et al. Neisseria gonorrhoeae and fosfomycin: Past, present and future. Int J Antimicrob Agents 2015,46（3）:290⁃296. doi: 10.1016/j.ijantimicag.2015.05.007.
［20］	Bala M, Singh V, Philipova I, et al. Gentamicin in vitro activity and tentative gentamicin interpretation criteria for the CLSI and calibrated dichotomous sensitivity disc diffusion methods for Neisseria gonorrhoeae［J］. J Antimicrob Chemother, 2016,71（7）:1856⁃1859. doi: 10.1093/jac/dkw102.
［21］	Ross J, Brittain C, Cole M, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea（G⁃ToG）: a randomised non⁃inferiority trial［J］. Lancet, 2019,393（10190）:2511⁃2520. doi: 10.1016/S0140⁃6736（18）32817⁃4.
［22］	Sood S, Agarwal SK, Singh R, et al. In vitro assessment of gentamicin and azithromycin⁃based combination therapy against Neisseria gonorrhoeae isolates in India［J］. J Med Microbiol, 2019,68（4）:555⁃559. doi: 10.1099/jmm.0.000953.
［23］	Livermore DM, Tulkens PM. Temocillin revived［J］. J Antimicrob Chemother, 2009,63（2）:243⁃245. doi: 10.1093/jac/dkn511.
［24］	Ghathian K, Calum H, Gyssens IC, et al. Temocillin in vitro activity against recent clinical isolates of Neisseria gonorrhoeae compared with penicillin, ceftriaxone and ciprofloxacin. J Antimicrob Chemother, 2016,71（4）:1122⁃1123. doi: 10.1093/jac/dkv434.
［25］	Chen MY, McNulty A, Avery A, et al. Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea（SOLITAIRE⁃U）: a randomised phase 3 non⁃inferiority trial［J］. Lancet Infect Dis, 2019,19（8）:833⁃842. doi: 10.1016/S1473⁃3099（19）30116⁃1.
［26］	Taylor SN, Marrazzo J, Batteiger BE, et al. Single⁃dose zoliflodacin（ETX0914） for treatment of urogenital gonorrhea［J］. N Engl J Med, 2018,379（19）:1835⁃1845. doi: 10.1056/NEJMoa1706988.
［27］	Theuretzbacher U, Barbee L, Connolly K, et al. Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea⁃challenges and opportunities［J］. Clin Microbiol Infect, 2020,26（12）:1630⁃1635. doi: 10.1016/j.cmi.2020.08.006.
［28］	Biedenbach DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens［J］. Antimicrob Agents Chemother, 2016,60（3）:1918⁃1923. doi: 10.1128/AAC.02820⁃15.
［29］	Scangarella⁃Oman NE, Hossain M, Dixon PB, et al. Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae［J］. Antimicrob Agents Chemother, 2018,62（12）. doi: 10.1128/AAC.01221⁃18.
［30］	Jacobsson S, Golparian D, Scangarella⁃Oman N, et al. In vitro activity of the novel triazaacenaphthylene gepotidacin（GSK2140944） against MDR Neisseria gonorrhoeae［J］. J Antimicrob Chemother, 2018,73（8）:2072⁃2077. doi: 10.1093/jac/dky162.
［31］	Taylor SN, Morris DH, Avery AK, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose⁃ranging, single⁃oral dose evaluation［J］. Clin Infect Dis, 2018,67（4）:504⁃512. doi: 10.1093/cid/ciy145.

[1]	李晓蝶朱琳洪毅勇黄影赖维龚子鉴. 不同实验条件对淋病奈瑟球菌体外转化效率的影响[J]. 中华皮肤科杂志, 2024, 57(3): 240-245.
[2]	卢琴黄美容杨慧张宁晴闵迅黄健. 鼻腔免疫淋病奈瑟球菌疫苗候选蛋白MetQ的免疫保护效果初步评估[J]. 中华皮肤科杂志, 2024, 57(3): 233-239.
[3]	郭蕾曹春艳方晓雅冯素英. 自身免疫性大疱病患者创面感染多重耐药菌现况及危险因素分析[J]. 中华皮肤科杂志, 2024, 57(2): 155-160.
[4]	马光荣谢红付刘家双周钟莲周淞麒黄莹雪李吉. 玫瑰痤疮患者小肠细菌过度生长情况调查及临床特征分析[J]. 中华皮肤科杂志, 2024, 57(2): 134-140.
[5]	朱邦勇周潜韦江平甘泉黄寅杰尹跃平徐文绮. 广西地区淋球菌临床分离株对庆大霉素的药物敏感性研究[J]. 中华皮肤科杂志, 2023, 56(8): 737-741.
[6]	李海洋林尽染刘庆梅倪春雅吴文育. 微生物群与头皮毛发疾病相关性研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 686-688.
[7]	夏灵尹卢琴王小素黄美容闵迅黄健. 淋病奈瑟菌NGO2105蛋白660 ~ 1 468肽段的表达纯化及多克隆抗体的制备与鉴定[J]. 中华皮肤科杂志, 2023, 56(3): 216-221.
[8]	李婷婷关猛猛赵娟康晓静. 单细胞转录组测序在黑素瘤研究中的应用[J]. 中华皮肤科杂志, 2023, 56(10): 977-981.
[9]	范文葛张青松叶迅魏梅范志江张静王玲薛峤陶晓瑜丁浩赵军. 男性阴茎附属腺和皮肤淋球菌感染皮损的高频超声研究[J]. 中华皮肤科杂志, 2022, 55(6): 528-531.
[10]	陈玉萍郑海林张之烽梅嬛刘维达刘沐桑. 南京某医院201株烟曲霉感染患者临床资料与唑类耐药情况回顾性分析[J]. 中华皮肤科杂志, 2022, 55(4): 316-320.
[11]	欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184.
[12]	陈绍椿刘经纬周可尹跃平. 头孢曲松耐药淋病奈瑟菌株FC428的流行、耐药机制及应对策略[J]. 中华皮肤科杂志, 2022, 55(12): 1122-1126.
[13]	杨璐段志敏李岷. 白念珠菌对棘白菌素类药物耐药机制的研究进展[J]. 中华皮肤科杂志, 2022, 55(12): 1114-1117.
[14]	丁甜甜崔宝红米淑宏张杨郑海林石继海刘维达. 浅部与深部感染来源白念珠菌氟康唑耐药株药物敏感性及耐药基因突变比较[J]. 中华皮肤科杂志, 2022, 55(10): 874-878.
[15]	邵丽丽刘全忠. 噬菌体疗法及其在皮肤和泌尿生殖道感染中的应用与展望[J]. 中华皮肤科杂志, 2021, 54(10): 924-927.

耐药淋球菌的备选治疗方案

Promising treatment options for antibiotic-resistant Neisseria gonorrhoeae

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

Metrics

本文评价

推荐阅读 10